ABSTRACT
Objective To investigate the COVID-19 mortality in Philippine provinces from 2020 to 2023.
Methods We calculated the crude (CMR) and age-standardised mortality rates (ASMR) of the Philippine provinces from the national COVID-19 surveillance data from January 18, 2020 to May 9, 2023. With Spearman’s method, we then performed a correlation analysis between the rates and four independent variables, namely, poverty incidence, population density, hospital beds per 100 000 population and proportion of elderly population (≥ 65).
Results The province with the highest ASMR is Benguet with 207.83 deaths per 100 000 population, followed by Cagayan, Bataan, Nueva Vizcaya, Quirino, National Capital Region, Isabela, Cebu, Aurora and Davao del Sur. Meanwhile, the province with the lowest ASMR is Tawi-Tawi with 2.22 deaths per 100 000 population, followed by Sulu, Masbate, Misamis Occidental, Camarines Norte, Sarangani, Camiguin, Sultan Kudarat, Southern Leyte, Catanduanes and Batanes. Among the independent variables, poverty incidence and hospital beds per 100 000 population were found to independently predict CMR and ASMR.
Discussion The results of this analysis provides a starting point for the investigation of COVID-19 mortality in Philippine provinces. The ranking of provinces by ASMR reveals the provinces with the highest and lowest rates, while the results of the correlation analysis, linked with findings from previous studies, explain the ranking, including surveillance issues that are related to health-care access and health-seeking behaviour. Our study paves the way for investigating factors that need to be considered and more closely investigated to get a clearer picture to inform decision-making, which affects millions of lives in communities across the Philippines’ provinces.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded through the SOS grants of the Office of the Vice Chancellor for Research and Development, University of the Philippines Diliman.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The publicly available national COVID-19 surveillance data of the Department of Health Philippines was used for this study. The dataset was last accessed on December 13, 2023 from https://doh.gov.ph/covid19tracker.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The publicly available national COVID-19 surveillance data used for this study was last accessed on December 13, 2023 from https://doh.gov.ph/covid19tracker. Upon checking on March 14, 2024, the link is no longer accessible.
